Geode Capital Management LLC lifted its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 5.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,164,037 shares of the company's stock after buying an additional 57,449 shares during the quarter. Geode Capital Management LLC owned about 2.23% of PROCEPT BioRobotics worth $93,751,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $32,000. Signaturefd LLC grew its stake in shares of PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $58,000. Arcadia Investment Management Corp MI bought a new position in PROCEPT BioRobotics in the 4th quarter worth approximately $64,000. Finally, Wilmington Savings Fund Society FSB bought a new position in PROCEPT BioRobotics in the 3rd quarter valued at $64,000. 89.46% of the stock is owned by institutional investors and hedge funds.
PROCEPT BioRobotics Trading Down 0.5 %
Shares of NASDAQ:PRCT traded down $0.25 during mid-day trading on Wednesday, reaching $52.67. 144,181 shares of the company's stock were exchanged, compared to its average volume of 776,243. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -26.98 and a beta of 1.09. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The business's fifty day moving average price is $60.08 and its 200-day moving average price is $75.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. On average, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.
Analyst Ratings Changes
PRCT has been the topic of several recent research reports. Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Truist Financial lowered their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $91.43.
Check Out Our Latest Analysis on PRCT
Insider Transactions at PROCEPT BioRobotics
In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 in the last quarter. 17.40% of the stock is currently owned by company insiders.
PROCEPT BioRobotics Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
